{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(10)"],"submitter":["Qian X"],"pubmed_abstract":["<h4>Background</h4>Stereotactic body radiotherapy (SBRT) is a precise and effective treatment for pulmonary oligometastases, offering high local control (LC) rates. However, the optimal SBRT dose when combined with immunotherapy remains unclear, and there is a lack of comprehensive studies focusing on dose optimization in this setting. This study addresses this knowledge gap by exploring different SBRT dose regimens and their impact on progression-free survival (PFS), overall survival (OS), and LC in patients receiving concurrent immunotherapy, offering novel insights into the synergistic effects of these treatments.<h4>Methods</h4>A retrospective cohort study was conducted of 101 patients with 141 pulmonary oligometastases treated from April 2018 to April 2022. Inclusion criteria included"],"journal":["Journal of thoracic disease"],"pagination":["7072-7085"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11565358"],"repository":["biostudies-literature"],"pubmed_title":["The optimal stereotactic body radiotherapy dose with immunotherapy for pulmonary oligometastases: a retrospective cohort study."],"pmcid":["PMC11565358"],"pubmed_authors":["Qian X","Ramirez RA","Fang Z","Jiang W","Lu Y","Chou J","Jabbour SK"],"additional_accession":[]},"is_claimable":false,"name":"The optimal stereotactic body radiotherapy dose with immunotherapy for pulmonary oligometastases: a retrospective cohort study.","description":"<h4>Background</h4>Stereotactic body radiotherapy (SBRT) is a precise and effective treatment for pulmonary oligometastases, offering high local control (LC) rates. However, the optimal SBRT dose when combined with immunotherapy remains unclear, and there is a lack of comprehensive studies focusing on dose optimization in this setting. This study addresses this knowledge gap by exploring different SBRT dose regimens and their impact on progression-free survival (PFS), overall survival (OS), and LC in patients receiving concurrent immunotherapy, offering novel insights into the synergistic effects of these treatments.<h4>Methods</h4>A retrospective cohort study was conducted of 101 patients with 141 pulmonary oligometastases treated from April 2018 to April 2022. Inclusion criteria included","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-07-16T23:00:01.857Z","creation":"2025-04-03T23:23:01.925Z"},"accession":"S-EPMC11565358","cross_references":{"pubmed":["39552865"],"doi":["10.21037/jtd-24-1624"]}}